New HIV vaccine duo enters first human safety trial
NCT ID NCT06919016
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing two experimental HIV vaccines, DV700P-RNA and DV701B1.1-RNA, for the first time in people. The study will enroll 45 healthy adults without HIV to check if the vaccines are safe and whether they trigger an immune response. Participants will receive a prime shot followed by a booster, and researchers will monitor side effects and immune system activity over about 16 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Two experimental HIV vaccines: DV700P-RNA (prime) and DV701B1.1-RNA (boost)
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine strategy that trains the immune system to fight the virus.
What could go wrong
This is a very early Phase 1 trial with only 45 people, so it is too soon to know if the vaccines will work. The main goal is safety, not proof of protection against HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital (Site ID: 30007)
Boston, Massachusetts, 02215, United States
-
Columbia P&S CRS (Site ID: 30329)
New York, New York, 10032, United States
-
Seattle Vaccine and Prevention CRS (Site ID: 30331)
Seattle, Washington, 98104, United States
-
The Hope Clinic of the Emory Vaccine Center CRS (Site ID: 31440)
Decatur, Georgia, 30030, United States
-
University of Alabama Medical Center (Site ID: 31788)
Birmingham, Alabama, 35222, United States
-
University of Pittsburgh (Site ID: 1001)
Pittsburgh, Pennsylvania, 15213, United States
-
University of Rochester Medical Center (Site ID: 31467)
Rochester, New York, 14642, United States
-
Vanderbilt University Medical Center (Site ID: 30352)
Nashville, Tennessee, 37232, United States